Login to Your Account



Amgen's Profits Up, but Shares Fall as FDA Seeks Prolia Data

By Donna Young


Friday, October 23, 2009
Amgen Inc.'s 24 percent increase in income in the third quarter was not enough to counter investors concerns Thursday about a second complete response letter for Prolia (denosumab) and new data suggesting there were higher rates of cancer deaths in chronic kidney disease patients administered the firm's erythropoiesis stimulating agent Aranesp (darbepoetin alfa). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription